Evidence map›Paper›PMID 33662837›Full record

ReviewDiabetes & metabolic syndrome

COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.

Rimesh Pal, Sanjay Kumar Bhadada, Anoop Misra

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. New-onset aplastic anemia after SARS-CoV-2 vaccination.International journal of hematology · 2023
    Review
  20. Sars-Cov-2 Infection in People with Type 1 Diabetes and Hospital Admission: An Analysis of Risk Factors for England.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rimesh PalDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Sanjay Kumar BhadadaDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: bhadadask@rediffmail.com.
Anoop MisraCentre of Nutrition & Metabolic Research (C-NET), National Diabetes, Obesity and Cholesterol Foundation (N-DOC), SDA, New Delhi, India; Diabetes Foundation (India), SDA, New Delhi, India; Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Chirag Enclave, Nehru Place, New Delhi, India. Electronic address: anoopmisra@gmail.com.
Post Graduate Institute of Medical Education and Research · INNational Diabetes Obesity and Cholesterol Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTo summarize the available evidence on the use COVID-19 vaccines in patients with diabetes mellitus.

methodsWe performed a thorough literature search with regard to COVID-19 vaccines in patients with type 1 and type 2 diabetes mellitus.

resultsThe novel coronavirus disease (COVID-19) tends to portend a poor prognosis in patients with diabetes mellitus (DM). Primary prevention remains the mainstay for mitigating the risks associated with COVID-19 in patients with DM. A significant step in primary prevention is timely vaccination. Routine vaccination against pneumococcal pneumonia, influenza, and hepatitis B is recommended in patients with DM with good efficacy and reasonable safety profile. With clinical data supporting a robust neutralizing antibody response in COVID-19 patients with DM, vaccination in individuals with DM is justified. In fact, as the burden of the disease is borne by people with DM, COVID-19 vaccination should be prioritized in individuals with DM. Multiple unresolved issues with regard to preferred vaccine type, vaccine efficacy and durability, frequency of administration, vaccination in children (<18 years) and pregnant/lactating women however remain, and need to be addressed through future research.

conclusionsPatients with type 1 and type 2 diabetes mellitus are at a high risk of poor prognosis with COVID-19 and vaccination should be prioritized in them. However, many unresolved issues with regard to COVID-19 vaccination need to be addressed through future research.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 22019-nCoV Vaccine mRNA-1273Ad26COVS1Antibodies, NeutralizingBNT162 VaccineChAdOx1 nCoV-19COVID-19COVID-19 VaccinesHumansRisk FactorsSARS-CoV-22019-nCoV Vaccine mRNA-1273Ad26COVS1Antibodies, NeutralizingBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesNVX-CoV2373 adjuvated lipid nanoparticleCOVID-19Diabetes mellitusVaccines

Identifiers

PMID33662837
PMCPMC7904463
OpenAlexW3129317947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.